-
Hypertension 09/2006; · 6.21 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Salt sensitivity of blood pressure is associated with an elevated risk of developing hypertension (HTN) and is an independent risk factor for cardiovascular disease. The prevalence of HTN increases after menopause. The aim of this study was to investigate prospectively whether the loss of ovarian hormones increases the occurrence of salt sensitivity among healthy premenopausal women. We enrolled 40 normotensive, nondiabetic women (age 47.2+/-3.5), undergoing hysterectomy-oophorectomy for nonneoplastic processes and not on hormone replacement, to determine the effect of changes in sodium intake on blood pressure the day before and subsequently 4 months after surgical menopause. Salt loading was achieved using a 2-L normal saline infusion and salt depletion produced by 40 mg of intravenous furosemide. A decrease >10 mm Hg in systolic blood pressure between salt loading and salt depletion was used to define salt sensitivity. Before and after menopause, salt-sensitive women exhibited higher waist/hip and waist/thigh ratios (P<0.01). Although all of the women remained normotensive, the prevalence of salt sensitivity was significantly higher after surgical menopause (21 women; 52.5%) than before (9 women; 22.5%; P=0.01), because 12 (38.7%) salt-resistant women developed salt sensitivity after menopause. In summary, we demonstrated that the prevalence of salt sensitivity doubled as early as 4 months after surgical menopause, without an associated increase in blood pressure. Epidemiological studies indicate that development of HTN may not occur until 5 to 10 years after menopause. The loss of ovarian hormones may unmask a population of women prone to salt sensitivity who, with aging, would be at higher risk for the subsequent development of HTN and cardiovascular disease.
Hypertension 07/2006; 47(6):1168-74. · 6.21 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This report describes an open randomized study intended to evaluate the long-term renoprotective effects of "standard" (80 mg once daily) versus "high" (80 mg twice daily) doses of telmisartan in hypertensive patients without diabetes with biopsy-proven chronic proteinuric nephropathies.
We included 78 patients (age, 43.5 +/- 13.2 years; 71.8% men). After a 4-week wash-out period, patients were randomly assigned to telmisartan, 80 mg once daily (n = 40) or 80 mg twice daily (n = 38), during a mean follow-up of 24.6 +/- 2.2 months.
Baseline characteristics were similar in both groups, including blood pressure, renal function, and proteinuria. Blood pressure control did not differ between groups during follow-up. In the group administered telmisartan, 80 mg once daily, serum creatinine level increased from 1.6 +/- 0.6 to 2.7 +/- 0.9 mg/dL (141 +/- 52 to 239 +/- 80 micromol/L), and estimated creatinine clearance declined from 68 +/- 30 to 50 +/- 34 mL/min (1.13 +/- 0.50 to 0.83 +/- 0.57 mL/s), whereas in those administered 80 mg twice daily, serum creatinine (1.6 +/- 0.7 to 1.6 +/- 0.8 mg/dL [141 +/- 62 to 141 +/- 71 micromol/L]) and estimated creatinine clearance values (67 +/- 38 to 74 +/- 38 mL/min [1.12 +/- 0.63 to 1.23 +/- 0.63 mL/s]) did not change during the study. The decrease in proteinuria was more pronounced (P < 0.01) in patients administered the high dose of telmisartan compared with those treated with the standard dose. Serum potassium levels and lipid profiles did not change significantly in either group.
Long-term administration of high doses of telmisartan seems to improve the efficacy of the drug to decrease proteinuria and slow the progression to end-stage renal failure in nondiabetic hypertensive renal disease.
American Journal of Kidney Diseases 12/2005; 46(6):1074-9. · 5.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Am J Hypertens (2003) 16, 107A–107A; doi:10.1016/S0895-7061(03)00354-6
P-189: Long-term safety and effectiveness of eprosartan in mild-to-moderate essential hypertensive patients. Eprosyst study
Pedro Aranda1, Francisco J. Aranda1, Esther Fernandez1 and Rafael Lozano11Hypertension Unit, University Regional Hospital Carlos Haya, Malaga, Spain; Medical Departament, Ferrer International, Barcelona, Spain
American Journal of Hypertension 04/2003; · 3.18 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Am J Hypertens (2002) 15, 136A–137A; doi:10.1016/S0895-7061(02)02644-4
P-293: Is there a metabolic hypertensive postmenopausal syndrome? Results of a national cross sectional study
Pedro Aranda1, Carlos Calvo1, Francisco Gude1, Antonio Coca1, Rafael Marin1, Francisco J. Aranda1, Maria T. Aguiler1 and Silvia Armengol1 MYRCA Investigator's Group1Spanish Hypertension Society, Madrid, Spain
American Journal of Hypertension 03/2002; · 3.18 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Am J Hypertens (2002) 15, 154A–154A; doi:10.1016/S0895-7061(02)02691-2
P-340: Plasma homocysteine levels, C677T polymorphism of the methylene-tetrahydrofolate reductase gene, Plasma Renin Activity and cardiovascular risk
Armando Reyes-Engel1, Miguel Morel1, Francisco J. Aranda1, Encarnación Muñoz-Moran1, Pedro Aranda1, M. Ruiz1, P. Muñoz1, Jose L. Dieguez1 and Nieves Fernandez -Arcas11Biocheeemistry and Molecular Biology, Faculty of Medicine, Malaga, Spain; Hypertension Unit, Carlos Haya Hospital, Malaga, Spain
American Journal of Hypertension 03/2002; · 3.18 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Am J Hypertens (2001) 14, 88A–88A; doi:10.1016/S0895-7061(01)01819-2
P-174: Effects of the combination trandolapril / verapamil versus enalapril/furosemide on renal function in elderly essential hypertensives with chronic renal failure
Francisco J. Aranda1, Pedro Aranda1, Manuel Manjon1, Juan C. Lopez1, Francisco Fernandez1, Enrique Heredia1, Manuel Lara1, Eduardo Lopez-Novales1 and Elena Blanco11Hypertension Unit Carlos Haya University Hospital Malaga, Malaga, Spain
American Journal of Hypertension 03/2001; · 3.18 Impact Factor
-
-
